



main: 617 • 674 • 5100 fax: 617 • 674 • 5101

**Massachusetts Biotechnology Council**  
300 Technology Square, Eighth Floor  
Cambridge, MA 02139

September 7, 2017

Dear Member of the Massachusetts Congressional Delegation:

On behalf of MassBio and its 1000+ member life sciences companies, academic institutions, service providers and patient organizations, I am writing to express our concerns regarding the Trump Administration's decision to rescind the Deferred Action for Childhood Arrivals (DACA) program, and urge swift congressional action on passage of the DREAM Act.

DACA has allowed 800,000+ young people, a population group known as "Dreamers", who came here as children, through no fault of their own and only know the U.S. as home, to stay here, obtain work and study permits, and contribute to the American economy. In deciding to end DACA, President Trump has put the lives of these hardworking young people, approximately 8,000 in Massachusetts, at great risk. If they lose DACA without permanent legislation in place, they will lose the ability to work legally and be subject to immediate deportation.

The immediate deportation of these people will not only negatively impact our economy now, but far into the future. This is especially true for the life sciences industry in Massachusetts where we project close to 12,000 additional jobs over the next five years. Our industry is already looking everywhere to hire the best and the brightest so they can research and develop the next generation of breakthrough cures and treatments. With this action, the talent pool shrinks and everyone is harmed.

We urge Congress to take the necessary steps to pass the DREAM Act, which would provide a permanent legislative solution and protect DACA and the "Dreamers" across the country. I look forward to working with you and the entire Massachusetts delegation to advocate for and advance policies that will allow people from around the world to join our industry and make a difference in patients' lives.

Thank you in advance for your consideration of this request. If you have any questions, please do not hesitate to contact me.

Sincerely,

Robert K. Coughlin  
President and CEO